...
首页> 外文期刊>Frontiers in Neuropharmacology >Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT1A-Mediated cAMP Signaling
【24h】

Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT1A-Mediated cAMP Signaling

机译:姜黄素衍生物J147的亚急性处理通过5-HT1A介导的CAMP信号传导改善抑郁症状的行为

获取原文
           

摘要

Major depressive disorder (MDD) is a severe mental disorder related to the deficiency of monoamine neurotransmitters, particularly to abnormalities of 5-HT (5-hydroxytryptamine, serotonin) and its receptors. Our previous study suggested that acute treatment with a novel curcumin derivative J147 exhibited antidepressant-like effects by increasing brain derived neurotrophic factor (BDNF) level in the hippocampus of mice. The present study expanded upon our previous findings and investigated the antidepressant-like effects of sub-acute treatment of J147 for 3 days in male ICR mice and its possible relevancy to 5-HT1A and 5-HT1B receptors and downstream cAMP-BDNF signaling. Methods: J147 at doses of 1, 3, and 9 mg/kg (via gavage) was administered for 3 days, and the anti-immobility time in the forced swimming and tail suspension tests (FST and TST) was recorded. The radioligand binding assay was used to determine the affinity of J147 to 5-HT1A and 5-HT1B receptor. Moreover, 5-HT1A or 5-HT1B agonist or its antagonist was used to determine which 5-HT receptor subtype is involved in the antidepressant-like effects of J147. The downstream signaling molecules such as cAMP, PKA, pCREB, and BDNF were also measured to determine the mechanism of action. Results: The results demonstrated that sub-acute treatment of J147 remarkably decreased the immobility time in both the FST and TST in a dose-dependent manner. J147 displayed high affinity in vitro to 5-HT1A receptor prepared from mice cortical tissue and was less potent at 5-HT1B receptor. These effects of J147 were blocked by pretreatment with a 5-HT1A antagonist NAD-299 and enhanced by a 5-HT1A agonist 8-OH-DPAT. However, 5-HT1B receptor antagonist NAS-181 did not appreciably alter the effects of J147 on depression-like behaviors. Moreover, pretreatment with NAD-299 blocked J147-induced increases in cAMP, PKA, pCREB, and BDNF expression in the hippocampus, while 8-OH-DPAT enhanced the effects of J147 on these proteins’ expression. Conclusion: The results suggest that J147 induces rapid antidepressant-like effects during a 3-day treatment period without inducing drug tolerance. These effects might be mediated by 5-HT1A-dependent cAMP/PKA/pCREB/BDNF signaling.
机译:主要抑郁症(MDD)是与单胺神经递质的缺乏有关的严重精神障碍,特别是5-HT(5-羟基特胺,血清素)及其受体的异常。我们以前的研究表明,用新型姜黄素衍生物J147的急性治疗通过增加小鼠海马的脑衍生的神经营养因子(BDNF)水平表现出抗抑郁药物。本研究扩展了我们之前的发现,并研究了J147的亚急性治疗在雄性ICR小鼠中的抗抑郁药物的抗抑郁药物,其可能与5-HT1A和5-HT1B受体和下游CAMP-BDNF信号传导的相关性。方法:施用1,3和9mg / kg(通过饲喂9mg / kg(通过饲养)的J147,记录强制游泳和尾悬架试验(FST和TST)中的抗分动时间。使用辐射配体结合测定法测定J147至5-HT1A和5-HT1B受体的亲和力。此外,使用5-HT1A或5-HT1B激动剂或其拮抗剂来确定哪种5-HT受体亚型参与J147的抗抑郁剂的效果。还测量了下游信号分子,如CAMP,PKA,PCREB和BDNF以确定作用机制。结果:结果表明,J147的亚急性治疗以剂量依赖性方式显着降低了FST和TST中的不动度时间。 J147在体外显示出从小鼠皮质组织制备的5-HT1A受体的高亲和力,并且在5-HT1B受体中较小。 J147的这些效果通过用5-HT1A拮抗剂NAD-299进行预处理而阻止,并通过5-HT1A激动剂8-OH-DPAT增强。然而,5-HT1B受体拮抗剂NAS-181未明显改变J147对抑郁状行为的影响。此外,NAD-299的预处理阻断了J147诱导的营地,PKA,PCREB和BDNF在海马中的表达增加,而8-OH-DPAT增强了J147对这些蛋白质表达的影响。结论:结果表明J147在3天治疗期间诱导快速抗抑郁效果而不诱导药物耐受性。这些效果可能由5-HT1A依赖性阵营/ PKA / PCREB ​​/ BDNF信号传导介导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号